Jeff67's quote: " The other option is to grant EUA with limitations depending on the data until further review. When the data is broken down and mortality is looked at with the Leronlimab patients there may be trends with those who had a high level of survival and conversely , those who had a higher level of dying, based on the 28 days. So do you continue to crunch data and delay an EUA with limitations then after reviewing 60 day data take an additional step ? Right now we are all speculating but the fda needs a win here in the mortality space and we are probably the closest thing to it. "
_______________________________________________

Yes, they could issue a partial EUA for Vyrologix for certain subsets but I have been thinking to myself about the 42 & 60 day readouts that the fda is now thinking of changing for CV trials of Mab's but, and don't get all snarled up if I say this but, what does this sound like to ya all, another possible delay the fda is putting on us, a non revenue start up bio-tech? I sure as heck this is not another hoop to go through as CYDY is not in the pockets of our fearless gov't agencies.

I know CYDY is in negotiations with (3) agencies and what I am saying or should I say I am thinking is for naught, I hope it's not another delay for us so other molecules from the biggies can slip in with an approval b4 CYDY.

I guess it's just the anxiety of all this that makes me, because of this wait, think of negatives and why so little was said in Monday's PR.

I don't know what to think with my huge pile of shares that I've held onto for so, so long.

Please correct me if I've gone wild or nonsensical - GLTU and all of us longs

HCIT